The association between structural brain alterations and serum testosterone levels in patients with type 2 diabetes mellitus

2019 ◽  
Vol 18 (1) ◽  
pp. e1440-e1441
Author(s):  
H.A. Atalay ◽  
L. Canat ◽  
M. Akarsu
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Serum Testosterone ◽  
Testosterone Levels ◽  
Structural Brain ◽  
Structural Brain Alterations

scholarly journals Reproductive Dysfunctions in Males with Type 2 Diabetes Mellitus: An Updated Review

EMJ Diabetes ◽  
2020 ◽  
pp. 79-89
Author(s):  
Sayantan Ray ◽  
Subhodip Pramanik
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Serum Testosterone ◽  
Fold Increase ◽  
Diabetic Patients ◽  
Testosterone Replacement Therapy ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Testosterone Levels

Deterioration in reproductive functions is one of the most serious complications of Type 2 diabetes mellitus (T2DM). Neuropathy, angiopathy, oxidative stress, and psychological deviation are the important causative factors in developing reproductive dysfunctions in diabetes. In males, the principal complications are erectile dysfunction (ED), ejaculatory disorders, and functional hypogonadism. Low serum testosterone is frequently observed in males with T2DM but the neuroendocrine pathophysiology is yet to be defined; this reduction in testosterone levels decreases libido. Evaluation of testosterone levels of male diabetic patients with hypogonadism symptoms is recommended. Hypogonadal males with diabetes might benefit from testosterone replacement therapy. However, there is a need for adequately powered long-term studies in this context. Impairment in sexual function is a common complication in males with diabetes. The pathophysiology of sexual dysfunction in diabetes is multifactorial. Males with diabetes have a >3-fold increase in the risk of ED compared to their nondiabetic counterparts. Phosphodiesterase type 5 inhibitors should be considered as first-line therapy in males with T2DM and ED. Nearly 50% of male diabetic patients presented some degree of subfertility or infertility. Alterations in sperm parameters and hormone levels can contribute to diabetes-related male infertility. Endocrinologists, diabetologists, and physicians should address sexual complaints of their patients since these problems can significantly impair their quality of life.

scholarly journals Serum testosterone levels in type 2 diabetes mellitus

2018 ◽  
Vol 6 (8) ◽  
pp. 409-413
Author(s):  
Dr. Dipankar Kundu ◽  
◽  
Dr. Enakshi Ghosh ◽  
Dr. Suparna Sinha Roy ◽  
Dr. Satyaki Basu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Serum Testosterone ◽  
Testosterone Levels

Cognitive functioning and structural brain abnormalities in people with Type 2 diabetes mellitus

2018 ◽  
Vol 35 (12) ◽  
pp. 1663-1670 ◽  
Author(s):  
B. Mankovsky ◽  
N. Zherdova ◽  
E. van den Berg ◽  
G.-J. Biessels ◽  
J. de Bresser
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cognitive Functioning ◽  
Brain Abnormalities ◽  
Structural Brain

scholarly journals Effect of Metformin on Testosterone Levels in Male Patients With Type 2 Diabetes Mellitus Treated With Insulin

2021 ◽  
Vol 12 ◽  
Author(s):  
Tingting Cai ◽  
Yun Hu ◽  
Bo Ding ◽  
Rengna Yan ◽  
Bingli Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycated Albumin ◽  
Control Group ◽  
Metformin Therapy ◽  
Testosterone Levels ◽  
Metformin Group ◽  
Male Patients

AimTo explore the chronic effects of metformin on testosterone levels in men with type 2 diabetes mellitus (T2DM).MethodsThis is a secondary analysis of a real-world study evaluating the efficacy and safety of premixed insulin treatment in patients with T2DM via 3-month intermittent flash glucose monitoring. Male patients aged 18-60 who were using metformin during the 3-month study period were included as the metformin group. The control group included males without metformin therapy by propensity score matching analysis with age as a covariate. Testosterone levels were measured at baseline and after 3-month treatment.ResultsAfter 3-month treatment, the control group had higher levels of total testosterone, free and bioavailable testosterone than those at baseline (P<0.05). Compared with the control group, the change of total (-0.82 ± 0.59 vs. 0.99 ± 0.59 nmol/L) and bioavailable (-0.13 ± 0.16 vs. 0.36 ± 0.16 nmol/L) testosterone levels in the metformin group significantly decreased (P=0.036 and 0.029, respectively). In Glycated Albumin (GA) improved subgroup, the TT, FT, and Bio-T levels in the control subgroup were higher than their baseline levels (P < 0.05). Compared with the metformin subgroup, TT level in the control subgroup also increased significantly (P=0.044). In GA unimproved subgroup, the change of TT level in the metformin subgroup was significantly lower than that in the control subgroup (P=0.040).ConclusionIn men with T2DM, 3-month metformin therapy can reduce testosterone levels, and counteract the testosterone elevation that accompanied with the improvement of blood glucose.Clinical Trial Registrationhttps://www.clinicaltrials.gov/ct2/show/NCT04847219?term=04847219&draw=2&rank=1.

Sign in / Sign up

Export Citation Format

Share Document